Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

14.55 +0.23 (+1.61%)

Delayed Quote Updated: 1:52 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Trevi Therapeutics, Inc. - Common Stock

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

March 26, 2025

From Avalo Therapeutics

Via GlobeNewswire

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock

September 06, 2024

Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?

Via MarketBeat

Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast

January 25, 2023

Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"),...

Via Newsfile

Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast

August 22, 2022

Phoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"),...

Via Newsfile

Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics

July 14, 2022

NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a...

From Traders News Source

Via AccessWire

5 Best Performing Micro-Cap Stocks Through the First Half of 2022

July 05, 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

Via Spotlight Growth

Topics Stocks

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.